MA53986A - Traitement de maladies neurologiques avec du zilucoplan - Google Patents

Traitement de maladies neurologiques avec du zilucoplan

Info

Publication number
MA53986A
MA53986A MA053986A MA53986A MA53986A MA 53986 A MA53986 A MA 53986A MA 053986 A MA053986 A MA 053986A MA 53986 A MA53986 A MA 53986A MA 53986 A MA53986 A MA 53986A
Authority
MA
Morocco
Prior art keywords
zilucoplan
treatment
neurological diseases
neurological
diseases
Prior art date
Application number
MA053986A
Other languages
English (en)
Inventor
Petra Duda
Ramin Farzaneh-Far
Zhong Ma
Alonso Ricardo
Evan Thackaberry
Nanqun Zhu
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of MA53986A publication Critical patent/MA53986A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/322—Retractable needles, i.e. disconnected from and withdrawn into the syringe barrel by the piston
    • A61M5/3234—Fully automatic needle retraction, i.e. in which triggering of the needle does not require a deliberate action by the user
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Environmental & Geological Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
MA053986A 2018-10-22 2019-10-22 Traitement de maladies neurologiques avec du zilucoplan MA53986A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862748659P 2018-10-22 2018-10-22
US201862777524P 2018-12-10 2018-12-10
US201962815575P 2019-03-08 2019-03-08
US201962837974P 2019-04-24 2019-04-24
US201962844388P 2019-05-07 2019-05-07
US201962899864P 2019-09-13 2019-09-13

Publications (1)

Publication Number Publication Date
MA53986A true MA53986A (fr) 2022-01-26

Family

ID=68696508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053986A MA53986A (fr) 2018-10-22 2019-10-22 Traitement de maladies neurologiques avec du zilucoplan

Country Status (13)

Country Link
US (2) US20220133841A1 (fr)
EP (1) EP3870221A1 (fr)
JP (2) JP2022508952A (fr)
KR (1) KR20210080390A (fr)
CN (1) CN113226368A (fr)
AU (1) AU2019365804A1 (fr)
BR (1) BR112021007083A2 (fr)
CA (1) CA3115828A1 (fr)
MA (1) MA53986A (fr)
MX (1) MX2021004366A (fr)
SG (1) SG11202103972SA (fr)
TW (1) TW202034943A (fr)
WO (1) WO2020086506A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3551210A1 (fr) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulateurs de l'activité du complément
EP3980047B1 (fr) 2019-06-04 2024-02-14 RA Pharmaceuticals, Inc. Traitement des maladies inflammatoires avec inhibiteurs du complément
WO2021050885A1 (fr) 2019-09-12 2021-03-18 Ra Pharmaceuticals, Inc. Traitement de maladies neurologiques avec des inhibiteurs de complément
AU2023265909A1 (en) 2022-05-05 2024-11-07 UCB Biopharma SRL Treatment of myasthenia gravis with zilucoplan
WO2023215587A1 (fr) 2022-05-05 2023-11-09 UCB Biopharma SRL Traitement de la myasthénie grave avec du zilucoplan
WO2024248042A1 (fr) 2023-05-29 2024-12-05 国立大学法人 東京大学 Nouveau composé ciblant musc et son utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388235B2 (en) * 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
WO2010025510A1 (fr) 2008-09-03 2010-03-11 Xenome Ltd Bibliothèques de conjugués peptidiques et leurs méthodes de fabrication
ES2895029T3 (es) * 2014-06-12 2022-02-17 Ra Pharmaceuticals Inc Modulación de actividad del complemento
HUE056613T2 (hu) 2015-01-28 2022-02-28 Ra Pharmaceuticals Inc Komplementaktivitás modulátorai
CN113543796A (zh) * 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
BR112021017820A2 (pt) * 2019-04-24 2022-02-08 Ra Pharmaceuticals Inc Composições e métodos para modulação da atividade de complemento
EP3980047B1 (fr) * 2019-06-04 2024-02-14 RA Pharmaceuticals, Inc. Traitement des maladies inflammatoires avec inhibiteurs du complément

Also Published As

Publication number Publication date
JP2025011136A (ja) 2025-01-23
MX2021004366A (es) 2021-08-16
US20220133841A1 (en) 2022-05-05
EP3870221A1 (fr) 2021-09-01
TW202034943A (zh) 2020-10-01
JP2022508952A (ja) 2022-01-19
BR112021007083A2 (pt) 2021-08-03
US20250032574A1 (en) 2025-01-30
AU2019365804A1 (en) 2021-05-20
SG11202103972SA (en) 2021-05-28
WO2020086506A1 (fr) 2020-04-30
CN113226368A (zh) 2021-08-06
CA3115828A1 (fr) 2020-04-30
KR20210080390A (ko) 2021-06-30

Similar Documents

Publication Publication Date Title
MA53986A (fr) Traitement de maladies neurologiques avec du zilucoplan
EP3419633A4 (fr) Traitement des pathologies oculaires allergiques avec des cyclodextrines
IL276383A (en) Treatment of ophthalmological diseases
IL262608A (en) Combination treatment of ocular inflammatory disorders and diseases
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
EP3720553C0 (fr) Dispositif de photobiomodulation destiné au traitement d'une maladie rétinienne
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
MA46061A (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
EP3273955A4 (fr) Traitement de maladies respiratoires
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
MA42930A (fr) Traitement de maladies neurodégénératives
EP3737363A4 (fr) Méthodes de traitement de maladies inflammatoires chroniques
EP3664789A4 (fr) Méthodes de traitement de maladies et de lésions des nerfs
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3344258A4 (fr) Traitement de maladies auto-immunes et de maladies auto-inflammatoires
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
EP3735209A4 (fr) Traitement de la progression de la myopie
EP3481411A4 (fr) Traitement du glaucome et d'autres maladies oculaires
EP3727369A4 (fr) Test théragnostique pour le traitement antifongique de maladies inflammatoires
GB201805100D0 (en) Treatment of sarcopenic diseases
EP3846855A4 (fr) Blocage du cd47 avec inhibition de la parp pour le traitement de maladies
MA52495A (fr) Nouveau traitement de maladies pulmonaires interstitielles
EP3413898A4 (fr) Utilisation de tréhalose pour le traitement de maladies neurologiques
EP3324890A4 (fr) Traitement du glaucome oculaire par l'intermédiaire d'implants intracamérulaires